Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102361 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1809284 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9911449 | 0.90 | CA1 (0.52) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2861782 | 0.90 | CA1 (0.52) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL20757550 | 0.86 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL628900 | 0.85 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL19558703 | 0.85 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5129984 | 0.85 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL628886 | 0.85 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5551451 | 0.85 | CTSK (0.45) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240317775-A1 | H4 Antagonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| EP-4259637-A1 | H4 ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-116396241-A | Preparation method of tert-butyl (R) -4-ethyl-2, 2-dioxide-1, 2, 3-oxathiazolidine-3-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2022129890-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129890-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| CN-110526930-B | anti-HIV (human immunodeficiency virus) sulfur-containing polycyclic-hydroxypyridone formamide analogue and application thereof | 莫云芬 | 2022-06-03 | — | — | CN | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2007-03-29 | — | — | US | disclosed |
| EP-1368357-A1 | TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| WO-2002068427-A1 | TRICYCLIC QUINOLINONE AND TRICYCLIC QUINOLINE AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-09-06 | — | — | WO | disclosed |
| US-5962695-A | ANTICOAGULANT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5866577-A | AN ANTICOAGULANT AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-02 | — | — | US | disclosed |
| US-5620991-A | ANTICOAGULANTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5576343-A | ANTICOAGULANTS; BLOOD-COAGULATION FACTOR X INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0540051-B1 | Aromatic amidine derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317775-A1 | H4 Antagonist Compounds | HRH4, HRH3, H1-4 | CTSK 3605/4885CTSS 3054/4885CA1 3922/4885 |
| US-20020183314-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | CTSK 2085/4885CTSS 1936/4885CA1 3568/4885 |
| US-20070072849-A1 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods | AR, NR5A1, FSHR | CTSK 2067/4885CTSS 1992/4885CA1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.